{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:10:57Z","timestamp":1779300657531,"version":"3.51.4"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bulcan.2026.01.021","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:49:38Z","timestamp":1773319778000},"page":"702-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ob\u00e9cabtag\u00e8ne autoleucel (Obe-cel) dans le traitement des leuc\u00e9mies aigu\u00ebs lymphoblastiques B en rechute ou r\u00e9fractaires"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2572-186X","authenticated-orcid":false,"given":"Lydia","family":"Cherfaoui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bulcan.2026.01.021_bib0030","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2026.01.021_bib0035","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard care for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1016\/j.bulcan.2026.01.021_bib0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19\u00a0for relapsed\/refractory adult B-cell acute lymphoblastic leukemia: phase 2\u00a0results from the single-arm, multicenter ZUMA-3\u00a0study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"10.1016\/j.bulcan.2026.01.021_bib0045","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bulcan.2022.09.006","article-title":"[New European approval: Brexucabtagene autoleucel in adult relapsed\/refractory acute lymphoblastic leukemia]","volume":"109","author":"Lemoine","year":"2022","journal-title":"Bull Cancer (Paris)"},{"issue":"23","key":"10.1016\/j.bulcan.2026.01.021_bib0025","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126001359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:57:47Z","timestamp":1779299867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126001359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0007455126001359"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.021","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ob\u00e9cabtag\u00e8ne autoleucel (Obe-cel) dans le traitement des leuc\u00e9mies aigu\u00ebs lymphoblastiques B en rechute ou r\u00e9fractaires","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}